Monitor Neurolief's revenue trajectory for potential $5 million equity tranche trigger and assess likelihood of BrainsWay exercising its acquisition option. The FDA approval and VA access create near-term commercial upside for Neurolief, which could significantly enhance BrainsWay's long-term value if it exercises its call option.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 26 $13.49entry
- T+1 · 8mo ago −4.60%α −2.92% · $12.87
- T+5 · 8mo ago +0.59%α −1.04% · $13.57
- T+20 · 7mo ago +21.35%α +10.68% · $16.37
- T+60 · 5mo ago +3.04%α −10.91% · $13.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's ProlivRx system for treatment-resistant major depressive disorder. This brings BrainsWay's total investment in Neurolief to $11 million, with potential for an additional $5 million equity investment and a call option to acquire Neurolief outright.
Key Facts
- BrainsWay invested an additional $6 million in Neurolief via a convertible loan, triggered by FDA PMA approval of ProlivRx for MDD.
- Total investment by BrainsWay in Neurolief now stands at $11 million.
- Potential for an additional $5 million equity investment if Neurolief hits a revenue-based target.
- BrainsWay holds a call option to acquire all of Neurolief at a price based on enterprise value or revenue multiple.
- ProlivRx is the first FDA-approved at-home neurostimulation device for treatment-resistant MDD.
- Neurolief has secured placement on the VA Federal Supply Schedule, enabling access to the U.S. veterans healthcare system.
Financial Impact
$6 million in new capital deployed; total exposure now $11 million with potential for $5 million more; possible future acquisition of Neurolief.
Risk Factors
- Execution risk in Neurolief's commercialization of ProlivRx despite FDA approval.
- Potential dilution or balance sheet impact if BrainsWay exercises future investment tranches or acquisition option.
- Regulatory or reimbursement challenges for at-home neurostimulation adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001925 |
| Document: f6k_032526.htm | 0001171843-26-001925 |
| Document: 0001171843-26-001925-index-headers.html | 0001171843-26-001925 |
| Document: 0001171843-26-001925-index.html | 0001171843-26-001925 |
| Document: 0001171843-26-001925.txt | 0001171843-26-001925 |
Track record
24 reports on BWAY
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers